Central insulin-like growth factor-1 (IGF-1) restores whole-body insulin action in a model of age-related insulin resistance and IGF-1 decline

Derek M. Huffman, Gabriela Farias Quipildor, Kai Mao, Xueying Zhang, Junxiang Wan, Pasha Apontes, Pinchas Cohen, Nir Barzilai

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Low insulin-like growth factor-1 (IGF-1) signaling is associated with improved longevity, but is paradoxically linked with several age-related diseases in humans. Insulin-like growth factor-1 has proven to be particularly beneficial to the brain, where it confers protection against features of neuronal and cognitive decline. While aging is characterized by central insulin resistance in the face of hyperinsulinemia, the somatotropic axis markedly declines in older humans. Thus, we hypothesized that increasing IGF-1 in the brain may prove to be a novel therapeutic alternative to overcome central insulin resistance and restore whole-body insulin action in aging. Utilizing hyperinsulinemic-euglycemic clamps, we show that old insulin-resistant rats with age-related declines in IGF-1 level demonstrate markedly improved whole-body insulin action, when treated with central IGF-1, as compared to central vehicle or insulin (P <0.05). Furthermore, central IGF-1, but not insulin, suppressed hepatic glucose production and increased glucose disposal rates in aging rats (P <0.05). Taken together, IGF-1 action in the brain and periphery provides a 'balance' between its beneficial and detrimental actions. Therefore, we propose that strategies aimed at 'tipping the balance' of IGF-1 action centrally are the optimal approach to achieve healthy aging and longevity in humans.

Original languageEnglish (US)
Pages (from-to)181-186
Number of pages6
JournalAging Cell
Volume15
Issue number1
DOIs
StatePublished - Feb 1 2016

Fingerprint

Somatomedins
Insulin Resistance
Insulin
Brain
Glucose
Glucose Clamp Technique
Hyperinsulinism
Liver

Keywords

  • Aging
  • Animal models
  • Central nervous system
  • Endocrinology
  • Glucose metabolism
  • Insulin resistance
  • Insulin-like growth factor

ASJC Scopus subject areas

  • Cell Biology
  • Aging

Cite this

Central insulin-like growth factor-1 (IGF-1) restores whole-body insulin action in a model of age-related insulin resistance and IGF-1 decline. / Huffman, Derek M.; Farias Quipildor, Gabriela; Mao, Kai; Zhang, Xueying; Wan, Junxiang; Apontes, Pasha; Cohen, Pinchas; Barzilai, Nir.

In: Aging Cell, Vol. 15, No. 1, 01.02.2016, p. 181-186.

Research output: Contribution to journalArticle

Huffman, Derek M. ; Farias Quipildor, Gabriela ; Mao, Kai ; Zhang, Xueying ; Wan, Junxiang ; Apontes, Pasha ; Cohen, Pinchas ; Barzilai, Nir. / Central insulin-like growth factor-1 (IGF-1) restores whole-body insulin action in a model of age-related insulin resistance and IGF-1 decline. In: Aging Cell. 2016 ; Vol. 15, No. 1. pp. 181-186.
@article{427a75bd3fc048a29d2615f3622c2315,
title = "Central insulin-like growth factor-1 (IGF-1) restores whole-body insulin action in a model of age-related insulin resistance and IGF-1 decline",
abstract = "Low insulin-like growth factor-1 (IGF-1) signaling is associated with improved longevity, but is paradoxically linked with several age-related diseases in humans. Insulin-like growth factor-1 has proven to be particularly beneficial to the brain, where it confers protection against features of neuronal and cognitive decline. While aging is characterized by central insulin resistance in the face of hyperinsulinemia, the somatotropic axis markedly declines in older humans. Thus, we hypothesized that increasing IGF-1 in the brain may prove to be a novel therapeutic alternative to overcome central insulin resistance and restore whole-body insulin action in aging. Utilizing hyperinsulinemic-euglycemic clamps, we show that old insulin-resistant rats with age-related declines in IGF-1 level demonstrate markedly improved whole-body insulin action, when treated with central IGF-1, as compared to central vehicle or insulin (P <0.05). Furthermore, central IGF-1, but not insulin, suppressed hepatic glucose production and increased glucose disposal rates in aging rats (P <0.05). Taken together, IGF-1 action in the brain and periphery provides a 'balance' between its beneficial and detrimental actions. Therefore, we propose that strategies aimed at 'tipping the balance' of IGF-1 action centrally are the optimal approach to achieve healthy aging and longevity in humans.",
keywords = "Aging, Animal models, Central nervous system, Endocrinology, Glucose metabolism, Insulin resistance, Insulin-like growth factor",
author = "Huffman, {Derek M.} and {Farias Quipildor}, Gabriela and Kai Mao and Xueying Zhang and Junxiang Wan and Pasha Apontes and Pinchas Cohen and Nir Barzilai",
year = "2016",
month = "2",
day = "1",
doi = "10.1111/acel.12415",
language = "English (US)",
volume = "15",
pages = "181--186",
journal = "Aging Cell",
issn = "1474-9718",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Central insulin-like growth factor-1 (IGF-1) restores whole-body insulin action in a model of age-related insulin resistance and IGF-1 decline

AU - Huffman, Derek M.

AU - Farias Quipildor, Gabriela

AU - Mao, Kai

AU - Zhang, Xueying

AU - Wan, Junxiang

AU - Apontes, Pasha

AU - Cohen, Pinchas

AU - Barzilai, Nir

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Low insulin-like growth factor-1 (IGF-1) signaling is associated with improved longevity, but is paradoxically linked with several age-related diseases in humans. Insulin-like growth factor-1 has proven to be particularly beneficial to the brain, where it confers protection against features of neuronal and cognitive decline. While aging is characterized by central insulin resistance in the face of hyperinsulinemia, the somatotropic axis markedly declines in older humans. Thus, we hypothesized that increasing IGF-1 in the brain may prove to be a novel therapeutic alternative to overcome central insulin resistance and restore whole-body insulin action in aging. Utilizing hyperinsulinemic-euglycemic clamps, we show that old insulin-resistant rats with age-related declines in IGF-1 level demonstrate markedly improved whole-body insulin action, when treated with central IGF-1, as compared to central vehicle or insulin (P <0.05). Furthermore, central IGF-1, but not insulin, suppressed hepatic glucose production and increased glucose disposal rates in aging rats (P <0.05). Taken together, IGF-1 action in the brain and periphery provides a 'balance' between its beneficial and detrimental actions. Therefore, we propose that strategies aimed at 'tipping the balance' of IGF-1 action centrally are the optimal approach to achieve healthy aging and longevity in humans.

AB - Low insulin-like growth factor-1 (IGF-1) signaling is associated with improved longevity, but is paradoxically linked with several age-related diseases in humans. Insulin-like growth factor-1 has proven to be particularly beneficial to the brain, where it confers protection against features of neuronal and cognitive decline. While aging is characterized by central insulin resistance in the face of hyperinsulinemia, the somatotropic axis markedly declines in older humans. Thus, we hypothesized that increasing IGF-1 in the brain may prove to be a novel therapeutic alternative to overcome central insulin resistance and restore whole-body insulin action in aging. Utilizing hyperinsulinemic-euglycemic clamps, we show that old insulin-resistant rats with age-related declines in IGF-1 level demonstrate markedly improved whole-body insulin action, when treated with central IGF-1, as compared to central vehicle or insulin (P <0.05). Furthermore, central IGF-1, but not insulin, suppressed hepatic glucose production and increased glucose disposal rates in aging rats (P <0.05). Taken together, IGF-1 action in the brain and periphery provides a 'balance' between its beneficial and detrimental actions. Therefore, we propose that strategies aimed at 'tipping the balance' of IGF-1 action centrally are the optimal approach to achieve healthy aging and longevity in humans.

KW - Aging

KW - Animal models

KW - Central nervous system

KW - Endocrinology

KW - Glucose metabolism

KW - Insulin resistance

KW - Insulin-like growth factor

UR - http://www.scopus.com/inward/record.url?scp=84955190089&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84955190089&partnerID=8YFLogxK

U2 - 10.1111/acel.12415

DO - 10.1111/acel.12415

M3 - Article

C2 - 26534869

AN - SCOPUS:84955190089

VL - 15

SP - 181

EP - 186

JO - Aging Cell

JF - Aging Cell

SN - 1474-9718

IS - 1

ER -